Primary Objectives:
1. Study the prognostic and predictive value of treatment efficacy based on changes in CTC counts during treatment (3 weeks after the start of treatment (immunotherapy and/or targeted therapy), compared to the pre-treatment CTC count (baseline).
2. Evaluation of the expression of informative melanoma antigens (e.g., Melan-A, S100, PDL1) and actionable mutations (e.g., BRAF).
Secondary Objectives:
3. Comparison between analyses of CTCs and circulating tumor DNA (ctDNA) collected at the same time points: plasma cell-free DNA (ctDNA) and intracellular DNA (CTC).
4. Expansion and analysis of melanoma CTCs in a specific culture microenvironment.
